Psychosis Mental and Behavioural Disorders Schizophrenia, schizotypal and delusional disorders
Conditions
Interventions
STUDY DESIGN
The study will be a single (rater) blind randomised feasibility study with two conditions
Attention Training Technique (ATT) plus treatment as usual (TAU) vs. TAU alone for people with psychosis. The trial will randomly allocate participants who meet criteria to a 12-week package of either
Sponsors
Greater Manchester Mental Health NHS Foundation Trust
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. In contact with community mental health services 2. Meets ICD-10 criteria for Schizophrenia, Schizoaffective Disorder, Delusional Disorder or other psychotic disorder not due to a substance or other or known physiological condition. 3. Score four+ on PANSS delusions/hallucinations items 5+ on suspiciousness/grandiosity 4. Help seeking 5. Willing and able to provide written informed consent 6. Aged 16 or above
Exclusion criteria
Exclusion criteria: 1. Moderate to severe learning disability (defined by care team e.g. Consultant Psychiatrist or Care-coordinator) 2. Organic impairment (defined by care team e.g. Consultant Psychiatrist or Care-coordinator) 3. Non-English speaking (this would prevent the use of standardised assessments) 4. Inpatient/acute psychiatric care needed 5. No care-coordinator or responsible clinician 6. Primary diagnosis of alcohol/substance dependence 7. Deaf or severely hard of hearing (preventing use of the audio task as part of ATT)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Recruitment as measured by number of referrals and number consenting and randomised; Timepoint: Baseline 2. Retention as measured by percentage follow-up and questionnaire response rates; Timepoint(s):; 6 weeks, 12 weeks, 6 and 12 months assessment points | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Attendance at intervention sessions, adherence to between session work as measured by number attended and between session tasks completed; Timepoint(s): 12 weeks 2. Qualitative interview exploring the personal experiences of involvement in the trial (including both arms) using the topic guide; Timepoint(s): 12 weeks + 3. Mental health symptoms – psychosis as measured by Positive and Negative Syndrome Scale (PANSS); anxiety & depression as measured by the Hospital Anxiety and Depression Scale (HADS); drug and alcohol use as measured by the Alcohol Use Disorders Identifical Tool (AUDIT) and Drug Use Disorders Identification Tool (DUDIT); Timepoint(s): 6 weeks, 12 weeks, 6 and 12 months assessment points 4. Metacognitive beliefs and processes as measured by Metacognitions Questionnaire (MCQ-30), Cognitive Attentional Syndrome Scale (CAS) Attentional Control Scale (ACS); Timepoint(s): 6 weeks, 12 weeks, 6 and 12 months assessment points 5. Recovery as measured by the Questionnaire about Process of Recovery (QPR), functioning as measured by the Global Assessment of Functioning (GAF) and quality of life as measured by the World Health Organisation Quality of Life measure (WHOQOL); Timepoint(s): 6 weeks, 12 weeks, 6 and 12 months assessment points | — |
Countries
United Kingdom
Outcome results
None listed